Need a specific person's email?
Browse Kineta's employee directory (about 32 employees) and reveal verified emails free.
Kineta's most common email format is FLast@kinetabio.com (ex. JDoe@kinetabio.com), used for 94% of kinetabio.com addresses. Kineta uses 6 email patterns across 2 domains: kinetabio.com and kineta.us. Percentages are the share of addresses within each domain.
| Format | Example | Share of kinetabio.com |
|---|---|---|
| FLast@kinetabio.comMost common | JDoe@kinetabio.com | |
| First@kinetabio.com | John@kinetabio.com | |
| FirstLast@kinetabio.com | JohnDoe@kinetabio.com |
| Format | Example | Share of kineta.us |
|---|---|---|
| FLast@kineta.usMost common | JDoe@kineta.us | |
| First@kineta.us | John@kineta.us | |
| LFirst@kineta.us | DJohn@kineta.us |
Browse Kineta's employee directory (about 32 employees) and reveal verified emails free.
Biotechnology ResearchWashington, United States11-50 Employees
Kineta is a clinical-stage biotechnology company focused on developing novel immunotherapies for oncology to address cancer immune resistance. The company is based in Seattle, Washington, United States, and employs between 11 and 50 people. It operates in the biotechnology research industry and maintains a website at https://kinetabio.com. Kineta has developed a VISTA-targeting monoclonal antibody program, including candidates such as KVA12123 (also referred to as KVA1213 in some sources), which has been studied in early-phase clinical settings. In June 2025, TuHURA Biosciences completed the acquisition of Kineta, with Kineta’s antibody asset renamed TBS-2025 as part of TuHURA’s late-stage immuno-oncology pipeline.
Most common format
FLast@kinetabio.com
Example: JDoe@kinetabio.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.